Den gennemsnitlige ændring fra baseline for HIV- 1- RNA og CD4- tal i uge 48 af behandlingen var næsten ens i begge behandlingsgrupper (- 3, 09 og - 3, 09 log10 kopier/ ml; +169 og 167 celler/ mm3 i hhv. tenofovirdisoproxil 245 mg (som fumarat) og stavudin gruppen).
The average change from baseline for HIV-1 RNA and CD4 count at 48 weeks of treatment was similar in both treatment groups (-3.09 and -3.09 log10 copies/ ml; +169 and 167 cells/ mm3 in the tenofovir disoproxil 245 mg (as fumarate) and stavudine groups, respectively).